Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Short Interest Down 16.6% in April

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the target of a significant decrease in short interest in the month of April. As of April 15th, there was short interest totalling 13,100 shares, a decrease of 16.6% from the March 31st total of 15,700 shares. Based on an average daily volume of 33,500 shares, the short-interest ratio is currently 0.4 days.

Cipher Pharmaceuticals Trading Up 0.2 %

Shares of CPHRF stock traded up $0.01 on Tuesday, hitting $6.24. The company had a trading volume of 1,849 shares, compared to its average volume of 18,546. The stock’s 50-day moving average is $6.02 and its two-hundred day moving average is $4.86. Cipher Pharmaceuticals has a twelve month low of $2.20 and a twelve month high of $7.37.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.